General Information of This Drug (ID: DMZ9BO8)

Drug Name
SR9011   DMZ9BO8
Synonyms
SR-9011; 1379686-29-9; CHEMBL1961797; 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide; 1-Pyrrolidinecarboxamide, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-n-pentyl-; GTPL8900; BDBM50366239; CS-4668; DB14014; SB19005; SR 9011; NCGC00347956-01; AK547296; AS-55867; HY-16988; Q15410183
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Preclinical [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
SR9011 + Idarubicin DCFL38K Idarubicin Glioblastoma? (Cell Line: T98G) [2]
SR9011 + Ruxolitinib DC7MP4K Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [3]
------------------------------------------------------------------------------------

References

1 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
2 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
3 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976